{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:26Z","timestamp":1794047486693,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>This study aimed to demonstrate the clinical outcomes of granulocyte colony-stimulating factor (G-CSF)\/antithymocyte globulin (ATG), posttransplantation cyclophosphamide (PTCy) and PTCy combined with low-dose ATG (PTCy with ATGlow)-based haploidentical transplantation protocols in patients with hematologic malignancies. The comparisons were conducted via propensity score matching (PSM) analysis to balance the basic characteristics among different groups and were based on the transplantation data reported to the Chinese Bone Marrow Transplantation Registry Group (CBMTRG) from January 2020 to December 2022. For each patient in the PTCy or PTCy with ATGlow group, patients (at a 1:2 ratio) from the G-CSF\/ATG group were selected. In total, the PTCy group (N=122) was matched with the G-CSF\/ATG group 1 (N=230), and the PTCy+ATGlow group (N=123) was matched with the G-CSF\/ATG group 2 (N=226). Compared with those in the PTCy group, the incidences of 28- day neutrophil engraftment (P=0.005), 100-day platelet engraftment (P=0.002), median time to neutrophil engraftment (P&lt;0.001) and platelet engraftment (P=0.011) were significantly greater in the G-CSF\/ATG group. No significant differences were observed in acute graft-versus-host disease (aGVHD) incidence or relapse incidence. In addition, patients in the G-CSF\/ ATG group had lower non-relapse mortality (NRM; P&lt;0.001), better 3-year overall survival (OS; P&lt;0.001) and leukemia-free survival (P&lt;0.001) rates than those in the PTCy group. Similarly, the G-CSF\/ATG group achieved lower NRM (P&lt;0.001) and better 3-year leukemia-free survival (P=0.002) than the PTCy+ATGlow group. In conclusion, G-CSF\/ATG-based haplo-HSCT may be a preferential choice for the Chinese population with hematologic malignancies. In the future, a randomized controlled study is needed for further confirmation.<\/jats:p>","DOI":"10.3324\/haematol.2024.286040","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:08:28Z","timestamp":1727953708000},"page":"629-639","source":"Crossref","is-referenced-by-count":7,"title":["Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group"],"prefix":"10.3324","volume":"110","author":[{"given":"Zheng-Li","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Nong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"73095","doi-asserted-by":"crossref","unstructured":"Wang XQ, Huang RH, Zhang XH, Zhang X. Current status and prospects of hematopoietic stem cell transplantation in China. Chinese Med J (Engl). 2022; 135(12):1394-1403.","DOI":"10.1097\/CM9.0000000000002235"},{"key":"73096","doi-asserted-by":"crossref","unstructured":"Chang YJ, Pei XY, Huang XJ. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol. 2022; 9(12):e919-e929.","DOI":"10.1016\/S2352-3026(22)00293-9"},{"key":"73097","doi-asserted-by":"crossref","unstructured":"Apperley J, Niederwieser D, Huang XJ. Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016; 22(1):23-26.","DOI":"10.1016\/j.bbmt.2015.11.001"},{"key":"73098","doi-asserted-by":"crossref","unstructured":"Dulery R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Rev. 2023; 62:101080.","DOI":"10.1016\/j.blre.2023.101080"},{"key":"73099","doi-asserted-by":"crossref","unstructured":"Zhang W, Gui R, Zu Y. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: a multicentre, randomized controlled clinical trial. Br J Haematol. 2023; 200(2):210-221.","DOI":"10.1111\/bjh.18483"},{"key":"73100","doi-asserted-by":"crossref","unstructured":"Barkhordar M, Kasaeian A, Janbabai G. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: a retrospective 10-year experience. Leuk Res. 2022; 120:106918.","DOI":"10.1016\/j.leukres.2022.106918"},{"key":"73101","doi-asserted-by":"crossref","unstructured":"Dulery R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Rev. 2023; 62:101080.","DOI":"10.1016\/j.blre.2023.101080"},{"key":"73102","doi-asserted-by":"crossref","unstructured":"Tsai XCH, Chen TT, Gau JP. Outcomes of different haploidentical transplantation strategies from the Taiwan Blood and Marrow Transplantation Registry. Cancers (Basel). 2022; 14(4):1097.","DOI":"10.3390\/cancers14041097"},{"key":"73103","doi-asserted-by":"crossref","unstructured":"Ruggeri A, Sun Y, Labopin M. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017; 102(2):401-410.","DOI":"10.3324\/haematol.2016.151779"},{"key":"73104","doi-asserted-by":"crossref","unstructured":"Nagler A, Kanate AS, Labopin M. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica. 2021; 106(6):1591-1598.","DOI":"10.3324\/haematol.2020.247296"},{"key":"73105","doi-asserted-by":"crossref","unstructured":"Tang F, Xu Y, Chen H. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF\/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Sci China Life Sci. 2020; 63(4):571-581.","DOI":"10.1007\/s11427-019-9594-7"},{"key":"73106","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-2919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"73107","doi-asserted-by":"crossref","unstructured":"Xu Z, Mo X, Kong Y. Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: a phase 2 trial. J Transl Int Med. 2023; 11(3):255-264.","DOI":"10.2478\/jtim-2023-0111"},{"key":"73108","unstructured":"Przepiorka D, Weisdorf D, Martin P. Consensus conference on acute GvHD grading. Bone Marrow Transplant. 1995; 15(6):825-828."},{"key":"73109","doi-asserted-by":"crossref","unstructured":"Liang M, Lyu ZS, Zhang YY. Activation of PPARdelta in bone marrow endothelial progenitor cells improves their hematopoiesis-supporting ability after myelosuppressive injury. Cancer Lett. 2024; 592:216937.","DOI":"10.1016\/j.canlet.2024.216937"},{"key":"73110","doi-asserted-by":"crossref","unstructured":"Huang T, Xu L, Zhang X. Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia. Br J Haematol. 2023; 200(4):494-505.","DOI":"10.1111\/bjh.18538"},{"key":"73111","doi-asserted-by":"crossref","unstructured":"Huo WX, Wen Q, Zhang XH. Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia. Br J Haematol. 2023; 202(4):856-865.","DOI":"10.1111\/bjh.18937"},{"key":"73112","doi-asserted-by":"crossref","unstructured":"Huang J, Feng B, Cheng Y. Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study. Bone Marrow Transplant. 2024; 59(1):147-149.","DOI":"10.1038\/s41409-023-02141-x"},{"key":"73113","doi-asserted-by":"crossref","unstructured":"Ruggeri A, Labopin M, Angelucci E. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transplant. 2021; 56(8):1842-1849.","DOI":"10.1038\/s41409-021-01248-3"},{"key":"73114","doi-asserted-by":"crossref","unstructured":"Ruggeri A, Galimard JE, Paina O. Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia. Transplant Cell Ther. 2021; 27(5):424.","DOI":"10.1016\/j.jtct.2021.01.016"},{"key":"73115","doi-asserted-by":"crossref","unstructured":"Ruggeri A, Santoro N, Galimard JE. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024; 109(7):2122-2130.","DOI":"10.3324\/haematol.2023.284445"},{"key":"73116","doi-asserted-by":"crossref","unstructured":"Battipaglia G, Labopin M, Blaise D. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2022; 28(9):587.","DOI":"10.1016\/j.jtct.2022.06.006"},{"key":"73117","doi-asserted-by":"crossref","unstructured":"Wang Y, Chang YJ, Chen L. Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ ATG induced GVHD protective activity and improve haploidentical transplant outcomes. Oncoimmunology. 2017; 6(11):1356152.","DOI":"10.1080\/2162402X.2017.1356152"},{"key":"73118","doi-asserted-by":"crossref","unstructured":"Makanga DR, Guillaume T, Willem C. Posttransplant cyclophosphamide and antithymocyte globulin versus posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution. J Immunol. 2020; 205(5):1441-1448.","DOI":"10.4049\/jimmunol.2000578"},{"key":"73119","doi-asserted-by":"crossref","unstructured":"El-Cheikh J, Devillier R, Dulery R. Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2020; 20(9):617-623.","DOI":"10.1016\/j.clml.2020.04.003"},{"key":"73120","doi-asserted-by":"crossref","unstructured":"Xue E, Lorentino F, Lupo Stanghellini MT. Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: A Pilot Study. J Clin Med. 2022; 11(4):1106.","DOI":"10.3390\/jcm11041106"},{"key":"73121","doi-asserted-by":"crossref","unstructured":"Dulery R, Goudet C, Mannina D. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2023; 58(4):386-392.","DOI":"10.1038\/s41409-022-01908-y"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286040\/77605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286040\/78101","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11777\/77605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:21Z","timestamp":1794046041000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286040","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}